IL10 and COVID-19: In a longitudinal study in 71 adults, IL-10 and IL-1 receptor antagonist (IL-1RA) were the only among a panel of 34 immune mediators that were increased as early as in the first week following the onset of clinical COVID-19 symptoms in those who developed severe disease (18 patients) beyond the second week compared to continued moderate disease (53 patients) (9).